School of Medicine


Showing 211-220 of 244 Results

  • Richard Roth

    Richard Roth

    Professor of Chemical and Systems Biology, Emeritus

    Current Research and Scholarly InterestsInsulin is one of the primary regulators of rapid anabolic responses in the body. Defects in the synthesis and/or ability of cells to respond to insulin results in the condition known as diabetes mellitus. To better design methods of treatment for this disorder, we have been focusing our research on how insulin elicits its various biological responses.

  • Stephen J. Roth

    Stephen J. Roth

    Professor of Pediatrics (Cardiology), Emeritus

    Current Research and Scholarly InterestsRandomized Therapeutic Trials in Pediatric Heart Disease, NIH/U01 GrantNo. HL68285 2001-2006.
    Heparin and the Reduction of Thrombosis (HART) Study. Pediatric Health Research Fund Award, Stanford Univ Sch of Medicine, 2005-2006.
    A Pilot Trial fo B-type Natriuretic Peptide for Promotion of Urine Output in Diuretic-Resistant Infants Following Cardiovascular Surgery.Pediatric Health Research Fund Award, Stanford Univ Sch of Medicine, 2005-2006.

  • Theodore Roth

    Theodore Roth

    Assistant Professor of Pathology

    Current Research and Scholarly InterestsThe Roth Lab develops, applies, and translates scalable genetic manipulation technologies in primary human cells and complex in vivo tissue environments. Working with students, trainees, and staff with backgrounds across bioengineering, genetics, immunology, oncology, and pathology, the lab has developed CRISPR-All, a unified genetic perturbation language able to arbitrarily and combinatorially examine genetic perturbations across perturbation type and scale in primary human cells. Ongoing applications of CRISPR-All in the lab have revealed surprising capacities to synthetically engineer human cells beyond evolved cellular states. These new capacities to perturb human cell’s genetics beyond their evolved functionality drives ongoing work to understand the biology and therapeutic potential of synthetic cell state engineering - in essence learning how to build new human genes tailor made for a specific cell and specific environment to drive previously inaccessible therapeutic cellular functions.

  • Walton T. Roth

    Walton T. Roth

    Professor of Psychiatry & Behavioral Sciences, Emeritus

    Current Research and Scholarly InterestsLaboratory and ambulatory recording of physiological, responses to stressors in anxious and phobic patients.

  • Corey Rovzar

    Corey Rovzar

    Instructor, Medicine - Stanford Prevention Research Center

    Current Research and Scholarly InterestsEnhancing human movement through scalable, remotely delivered physical activity interventions, remote assessment and monitoring of human movement, health technology development, fall prevention, aging, digital balance assessment, improving access to health and healthcare, increasing healthspan, lifestyle medicine

  • Mohana Roy, MD

    Mohana Roy, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in oncology, including in Carcinoma of Unknown Primary (CUP).

    Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience, given how the complex process of getting cancer care can be made a bit more seamless. She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.

    She had led major efforts in the cancer program including starting standardized discharge follow up for patients after hospitalization, starting same day clinical care at the cancer center, and also expediting care for patients with an unclear diagnosis of cancer but with suspected imaging concerns.

    Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs), through distress screening with the Stanford Medicine Cancer Center, and in care for patient with limited English proficiency.

    Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford, where she was chief fellow.